Loading
A phase 3 trial of Volrustomig in cervical cancer, run by AstraZeneca, now recruiting.
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) is a phase 3 interventional study registered as NCT06079671 by AstraZeneca, with 800 participants planned, started 2023-09-22 and due to reach its primary completion in 2027-11-26. Interventions recorded: Volrustomig.
Shares Locally advanced cervical cancer, AstraZeneca, Cervical cancer and the tag pipeline.
Shares Locally advanced cervical cancer, Cervical cancer and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Cervical cancer and the tag pipeline.